PROGRAM DESCRIPTION:
This CME conference is a unique medical meeting that brings world-renowned clinical leaders in diabetes and cardiovascular disease and practicing clinicians together to improve the care of patients at a high risk of cardiovascular, metabolic, and kidney diseases. This program is designed to evaluate the clinical science aspects of diabetes, obesity, and CVD, focusing on the heart and kidney in diabetes. The goal is to develop appropriate, comprehensive clinical management plans aligning endocrinologists, cardiologists, nephrologists and all other interested clinicians in their understandings of the impact of diabetes and CVD outcome trials on the clinical management of these very high-risk patients.

PROGRAM OBJECTIVES: Upon completion of this meeting, participants should be able to:

- Discuss the role of incretins in the management of obesity, diabetes, and its complications
- Evaluate the evidence supporting the use of SGLT2 inhibitors and GLP1-RAs to reduce cardiovascular mortality in patients with T2D
- Evaluate the evidence supporting the use of SGLT2 inhibitors for HF prevention
- Evaluate the extent of vascular disease in diabetes and cardiometabolic syndrome
- Evaluate the extent of macro and microvascular disease in diabetes and obesity
- Provide comprehensive management of diabetes, addressing obesity, hypertension, and dyslipidemia as well as glucose
- Discuss changes in lipid management guidelines
- Evaluate the impact on the clinical practice of new CV outcome trials in patients with diabetes, including CANVAS, LEADER, SUSTAIN 6, and EMPA-REG
- Evaluate the impact on the clinical practice of lipid CV outcome trials, including IMPROVE-IT, FOURIER, REDUCE-IT, ODYSSEY-Outcomes
- Implement the best practices for the management of HFrEF
- Describe the relationship between diabetes, obesity, and congestive heart failure
- Describe the role of PCSK9 in lipid elevations and their potential contributions to vascular disease
- Understand the mechanism of action of PCSK9 inhibitors and CETP inhibitors and their impact on CVD
- Design appropriate insulin-based therapeutic regimens for patients with type 2 diabetes
- Describe obesity management based on a complications-centric model
- Evaluate bariatric procedures and surgery as well as devices, and their effect on weight loss, hormones, and long-term outcomes
- Describe optimal use of glucose monitoring devices

TARGET AUDIENCE
This educational initiative is designed for endocrinologists, cardiologists, diabetologists, nephrologists, internists, family physicians, nurse practitioners, physician assistants, and other healthcare professionals interested in the prevention and treatment of diabetes, obesity, cardiovascular disease, and associated conditions, as well as the effect of these conditions on health and society.

HEART IN DIABETES PROGRAM COMMITTEE
Yehuda Handelsman, MD, Chair • Mikhail N. Kosiborod, MD, Chair • Deepak L. Bhatt, MD • Zachary T. Bloomgarden, MD
• Biykem Bozkurt, MD, PhD • Matthew J. Budoff, MD • Javed Butler, MD • David Cherney, MD, PhD • Robert J. Chilton, DO
• Mark E. Cooper, AO, PhD • Michael H. Davidson, MD • Ralph A. DeFronzo, MD • Daniel Einhorn, MD • Michael E. Farkouh, MD
• Sergio Fazio, MD, PhD • Vivian A. Fonseca, MD • Alan J. Garber, MD, PhD • Peter J. Grant, MD • George Grunberger, MD
• Silvio E. Inzucchi, MD • Paul S. Jellinger, MD • Mark Kearney, MD • Lawrence A. Leiter, MDCM • Norman E. Lepor, MD
• Derek LeRoith, MD, PhD • Christos S. Mantzoros, MD, DSc, PhD • Nikolaus Marx, MD • Darren K. McGuire, MD
• Christian W. Mende, MD • Richard E. Pratley, MD • Kausik Ray, MD • Peter Reaven, MD
• Laurence Sperling, MD • Matthew R. Weir, MD • Renee S. Asp, BS
## PROGRAM 2020

**FRIDAY AUGUST 7, 2020**

### 9:00am — 1:30pm
- **Registration**

### 12:00PM — 1:00PM
**NON-CME LUNCH SESSION**
- Supported by: Amarin

### 12:15PM
**EXHIBIT HALL OPENS**

### 1:15pm — 1:25pm
- **Welcome & Introduction**
  - Yehuda Handelsman, MD • Mikhail N. Kosiborod, MD

### 1:25pm — 1:35pm
- **Pre-CME Questions**

### SESSION 1
**WOMEN & CVD**
- **Chairs:** Daniel Einhorn, MD • Norman E. Lepor, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:35pm — 1:55pm</td>
<td>Cardiovascular Disease Risk Reduction in Menopausal Women</td>
<td>Gina P. Lundberg, MD</td>
</tr>
<tr>
<td>1:55pm — 2:15pm</td>
<td>Gender Differences in Cardiovascular Imaging</td>
<td>Matthew J. Budoff, MD</td>
</tr>
<tr>
<td>2:15pm — 2:35pm</td>
<td>Sex Differences in DM &amp; CVD Across Outcome Studies</td>
<td>Neha J. Pagidipati, MD</td>
</tr>
<tr>
<td>2:35pm — 2:55pm</td>
<td>Q&amp;A Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION 2
**HEART IN DIABETES WITH CIRCULATION**
- **Chair:** Biykem Bozkurt, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:55pm — 3:05pm</td>
<td>Introduction</td>
<td>Biykem Bozkurt, MD, PhD</td>
</tr>
<tr>
<td>3:05pm — 3:20pm</td>
<td>GLP1ra Exenatide and Heart Failure Outcomes</td>
<td>Robert J. Mentz, MD</td>
</tr>
<tr>
<td>3:20pm — 3:35pm</td>
<td>The Diabetes Paradox in Aortic Aneurysm</td>
<td>Joshua Beckman, MD</td>
</tr>
<tr>
<td>3:35pm — 4:05pm</td>
<td>REFRESHMENT BREAK AT EXHIBIT HALL</td>
<td></td>
</tr>
<tr>
<td>4:05pm — 4:20pm</td>
<td>Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of CVD in T1DM</td>
<td>Myra A. Lipes, MD</td>
</tr>
<tr>
<td>4:20pm — 4:35pm</td>
<td>Can We Predict Who Can Benefit from SGLT2i in Heart Failure? Heart Failure Risk Stratification and Efficacy of SGLT2i in Patients with T2DM</td>
<td>Benjamin M. Scrira, MD</td>
</tr>
<tr>
<td>4:35pm — 4:50pm</td>
<td>Sugar and Artificially-Sweetened Beverages and CVD Risk - Reason for Concern?</td>
<td>Alice H. Lichtenstein, D.Sc</td>
</tr>
<tr>
<td>4:50pm — 4:55pm</td>
<td>Wrap-up/Ask the Editor</td>
<td>Biykem Bozkurt, MD, PhD</td>
</tr>
</tbody>
</table>

### SESSION 3
**CONTEMPORARY CONCEPTS & MANAGEMENT OF DM & ASCVD**
- **Chairs:** Laurence Sperling, MD • Nikolaus Marx, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:55pm — 5:15pm</td>
<td>Epigenetic Modification to Reduce CVD in People with DM</td>
<td>Kausik Ray, MD</td>
</tr>
<tr>
<td>5:15pm — 5:35pm</td>
<td>The Surgical Management of CAD in DM</td>
<td>Michael E. Farkouh, MD</td>
</tr>
<tr>
<td>5:35pm — 5:55pm</td>
<td>Update on CVOTs</td>
<td>Michael H. Davidson, MD</td>
</tr>
<tr>
<td>5:55pm — 6:05pm</td>
<td>Cardio-Metabolic Centers Alliance</td>
<td>Mikhail N. Kosiborod, MD</td>
</tr>
<tr>
<td>6:05pm — 6:30pm</td>
<td>Q&amp;A Panel Discussion/Post-CME Questions</td>
<td></td>
</tr>
</tbody>
</table>

### 6:30PM — 7:30PM
**WELCOME AND POSTERS RECEPTION AT EXHIBIT HALL**

### 7:30PM — 8:30PM
**NON-CME DINNER SESSION**
- Supported by: Janssen

### SATURDAY AUGUST 8, 2020

### 6:45AM — 7:45AM
**NON-CME BREAKFAST SESSION**
- Supported by: Abbott

### 7:00AM — 8:00AM
**REGISTRATION • COFFEE AT EXHIBIT HALL**

### 8:00am — 8:10am
- Pre-CME Questions

### SESSION 4
**GLP1-RA IN ASCVD & THE KIDNEY**
- **Chairs:** Stefano Del Prato, MD • Richard E. Pratley, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:10am — 8:30am</td>
<td>Mechanistic Insights into Cardiovascular Effects of GLP1-ra</td>
<td>Nikolaus Marx, MD</td>
</tr>
<tr>
<td>8:30am — 8:50am</td>
<td>GLP1-ra Impact on the Kidney</td>
<td>Mark E. Cooper, PhD</td>
</tr>
<tr>
<td>8:50am — 9:00am</td>
<td>Role of GLP1-ra in Trials in HF Patients</td>
<td>Javed Butler, MD</td>
</tr>
<tr>
<td>9:00am — 9:15am</td>
<td>Q&amp;A Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION 5
**TECHNOLOGY & DIGITAL HEALTH**
- **Chairs:** Christos S. Mantzoros, MD, PhD • Robert J. Chilton, DO

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:15am — 9:35am</td>
<td>Artificial Intelligence In The Future Management of Cardiovascular Disease and Diabetes</td>
<td>Irving K. Loh, MD</td>
</tr>
<tr>
<td>9:35am — 9:55am</td>
<td>The Implication of Digital Health for Cardiometabolic Conditions</td>
<td>Michael P. Snyder, PhD</td>
</tr>
<tr>
<td>9:55am — 10:15am</td>
<td>Is There an App for That? Role of Devices on Diabetes and CVD Management</td>
<td>George Grunberger, MD</td>
</tr>
<tr>
<td>10:15am — 10:30am</td>
<td>Q&amp;A Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### 10:30AM — 11:00AM
**REFRESHMENT BREAK AT EXHIBIT HALL**
**SESSION 6**  
**CONTROVERSIES IN LIPID MANAGEMENT**  
Chairs: Paul S. Jellinger, MD • Kausik Ray, MD

11:00am — 11:20am  
“Back to the Future” with Lipid Therapy  
Norman E. Lepor, MD

11:20am — 11:40am  
Should High Triglycerides Be Managed in Addition to a Statin & EPA?  
Sergio Fazio, MD, PhD

**DEBATE: SHOULD TREATMENT WITH PCSK9I BE RESERVED FOR LDL > 100?**

11:40am — 11:55am  
Yes  
Jennifer G. Robinson, MD

11:55am — 12:10pm  
No  
Steven E. Nissen, MD

12:10pm — 12:15pm  
Rebuttal

12:15pm — 12:20pm  
Rebuttal

12:20pm — 12:40pm  
Q+A Panel Discussion

**12:40PM — 1:40PM**  
**NON-CME LUNCH SESSION**  
Industry Supported: AstraZeneca

**SESSION 7**  
**ADVANCES IN ANTI-THROMBOTICS IN DIABETES**  
Chairs: Deepak L. Bhatt, MD • Michael H. Davidson, MD

1:40pm — 2:00pm  
Insights on Anti-thrombotic Strategies in Diabetes from THEMIS and THEMIS PCI  
Philippe Gabriel Steg, MD

2:00pm — 2:20pm  
Anti-Thrombotic Therapy in Diabetes  
Richard C. Becker, MD

2:20pm — 2:40pm  
COMPASS  
Deepak L. Bhatt, MD

2:40pm — 2:55pm  
Q+A Panel Discussion

**2:55PM — 3:30PM**  
**AWARD PRESENTATION “LUMINARY IN CARDIOMETABOLIC MEDICINE”**  
Presented by: Deepak L. Bhatt, MD • Mikhail N. Kosiborod, MD • Yehuda Handelsman, MD  
**KEY NOTE: SGTL2 and the Birth of 2 PARADIGM SHIFTS in Clinical Care**  
Eugene Braunwald, MD

**3:30PM — 4:00PM**  
**REFRESHMENT BREAK AT EXHIBIT HALL**

**SESSION 8**  
**THE LIVER & THE HEART**  
Chairs: Derek Lefkothi, MD, PhD • Matthew R. Weir, MD

4:00pm — 4:20pm  
NAFLD & the Heart as a Part of the Spectrum of Cardiometabolic Risk  
Laurence Sperling, MD

4:20pm — 4:40pm  
Emerging Management Options for NAFLD/NASH - Impact on Cardiometabolic Outcomes  
Christos S. Mantzoros, MD, PhD

4:40pm — 4:50pm  
Q+A Panel Discussion

**SESSION 9**  
**HEART IN DIABETES WITH JACC**  
Chairs: Michael E. Farkouh, MD

4:50pm — 5:00pm  
Introduction  
Michael E. Farkouh, MD

5:00pm — 5:15pm  
Atrial Fibrillation and Diabetes Mellitus  
Allen Wang, MD

5:15pm — 5:30pm  
Therapeutic Care, Health-Related Quality of Life,  
& Clinical Outcomes in Comorbid HFpEF and DM: The CHAMP-HR Registry  
Muthiah Vaduganathan, MD

5:30pm — 5:45pm  
Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes  
Daniel Gudbjartsson, PhD

5:45pm — 6:00pm  
SGTL2 Inhibition and Cardiorenal Protection  
Julie A. Lovshin, MD, PhD

6:00pm — 6:15pm  
Individualizing Revascularization Strategy for Diabetic Patients with Multivessel CAD  
David J. Cohen, MD

6:15pm — 6:20pm  
Wrap-up/Ask the Editor

6:20pm — 6:30pm  
Post-CME Questions

**6:30PM — 7:30PM**  
**NON-CME DINNER SESSION**  
Industry Supported: TBD

**7:30PM — 9:30PM**  
**CME DINNER SYMPOSIUM: THE PREVENTION AND MANAGEMENT OF HEART FAILURE**  
SUPPORTED BY: ASTRAZENECA

Chairs: Yehuda Handelsman, MD • Javed Butler, MD

7:30pm — 7:45pm  
Introduction/Pre-CME Questions

7:45pm — 8:05pm  
Epidemiology and Pathophysiology of HF  
Mikhail N. Kosiborod, MD

8:05pm — 8:25pm  
Preventing HF & HF Adverse Outcomes: A Look at the Evidence  
Javed Butler, MD

8:25pm — 8:45pm  
The Present and Future Management of HFrEF and HfPEF  
Biykem Bozkurt, MD, PhD

8:45pm — 9:15pm  
Panel Discussion and Q&A: Practical Management of HF — Case-Based  
Panel: Biykem Bozkurt, MD, PhD, Yehuda Handelsman, MD, Mark Kearney, MD,  
Mikhail N. Kosiborod, MD, Christian W. Mende, MD, Muthiah Vaduganathan, MD  
Moderator: Javed Butler, MD

9:15pm — 9:30pm  
Post-CME Questions/Concluding Remarks
SUNDAY AUGUST 9, 2020

8:00am – 8:10am  Pre-CME Questions

8:10am – 8:15am  ORAL ABSTRACT WINNERS AWARD PRESENTATION

SESSION 10  MANAGEMENT OF HYPERGLYCEMIA TO IMPROVE OUTCOMES
Chairs: Zachary T. Bloomgarden, MD • Peter J. Grant, MD

8:15am – 8:25am  Preventing Diabetes to Prevent CVD: Is it Chicken or Egg? (or Turkey?!)
Silvio E. Inzucchi, MD

8:25am – 8:35am  Managing Hyperglycemia in T2DM with CKD 4-5
Vivian A. Fonseca, MD

8:35am – 8:45am  The Combination of SGLT2i and GLP1-ra’s Impact on CVD
Ralph A. DeFranzo, MD

8:45am – 8:55am  Adjunctive Therapies for Type 1 Diabetes: Thinking Beyond Glucose Control
Richard E. Pratley, MD

8:55am – 9:05am  Q+A Panel Discussion

SESSION 11  THE TREATMENT OF DIABETES
Chairs: Ralph A. DeFranzo, MD • George Grunberger, MD

DEBATE: EARLY COMBINATION VS SEQUENTIAL THERAPY - IMPACT ON DM & CVD

9:05am – 10:15am  Sequential Therapy
David M. Nathan, MD

10:15am – 10:35am  Early Combination Therapy
Stefano Del Prato, MD

10:35am – 10:50am  Q+A Panel Discussion

10:50am – 11:10am  REFRESHMENT BREAK

SESSION 12  THE KIDNEY & THE HEART
Chairs: Mark E. Cooper, PhD • Christian W. Mende, MD

11:10am – 11:30am  The Role of Sodium Restriction in HF in Type 2 Diabetes
Jeffrey Testani, MD

11:30am – 11:50am  Effect of SGLT2i on BP and CKD Progression: Is it Dependent or Independent of BP?
Matthew R. Weir, MD

11:50am – 12:10pm  How Do SGLT2i Reduce Cardiovascular Outcomes and Atrial Fibrillation
Subodh Verma, MD, PhD

12:10pm – 12:30pm  Impact of Kidney Function on Mortality in the CVOTs
George L. Bakris, MD

12:30pm – 12:50pm  Q+A Panel Discussion

12:50pm – 1:45pm  INDUSTRY SUPPORTED SESSION – TBD

SESSION 13  HEART FAILURE: STATE-OF-THE-ART
Chairs: Matthew J. Budoff, MD • Vivian A. Fonseca, MD

1:45pm – 2:05pm  Impact of Blood Pressure Variability on CHF
Peter Reaven, MD

2:05pm – 2:25pm  HF in DMP: Is it Morbidity Not Mortality We Need to Focus on?
Mark Kearney, MD

2:25pm – 2:45pm  Physiologic Monitoring of Heart Failure
Robert J. Chilton, DO

2:45pm – 3:05pm  DAPA-HF and Next Steps with SGLT2 Inhibitors in Heart Failure
John McMurray, MD

3:05pm – 3:25pm  Q+A Panel Discussion

3:25pm – 3:40pm  REFRESHMENT BREAK

SESSION 14  PRACTICE RECOMMENDATIONS IN DIABETES & ASCVD – AN UPDATE
Chairs: Silvio E. Inzucchi, MD • Sergio Fazio, MD, PhD • Mikhail N. Kosiborod, MD

3:40pm – 3:55pm  Contemporary Lipid Management Recommendations in the Prevention of CVD
Christie M. Ballantyne, MD

3:55pm – 4:10pm  ESC/EASD 2019 CVD in DM Guidelines
Peter J. Grant, MD

4:10pm – 4:25pm  ADA-EASD Practice Recommendations’ 2019 Update
David A. D’Alessio, MD

4:25pm – 4:40pm  AACE 2020 DM & Lipid Algorithm
Yehuda Handelsman, MD

4:40pm – 5:00pm  Q+A Panel Discussion/Post-CME Questions

5:00PM  ADJOURN
FACULTY 2020

Yehuda Handelsman, MD  
FACP, FNLA, FASPC, MACE  
Chair & Program Director  
4th Heart in Diabetes  
Medical Director & Principal Investigator  
The Metabolic Institute of America  
Tarzana, California

Mikhail N. Kosiborod MD,  
FACC, FAHA  
Chair & Program Director  
4th Heart in Diabetes  
Professor of Medicine  
Saint Luke’s Mid America Heart Institute  
University of Missouri-Kansas City  
School of Medicine  
Kansas City, Missouri

George L. Bakris, MD, MA  
Hon. DSc, FASN, FAHA  
Professor of Medicine  
Director, AHA Comprehensive  
Hypertension Center  
The University of Chicago Medicine  
Chicago, Illinois

Christie M. Ballantyne, MD  
FACP, FACC  
Chief, Sections of Cardiology and  
Cardiovascular Research  
Professor, Departments of Medicine  
Genetics and Physiology  
Director, Center for Cardiometabolic  
Disease Prevention  
Baylor College of Medicine  
Houston, Texas

Richard C. Becker, MD, FAHA  
Professor of Medicine  
Director, Division of Cardiovascular Health  
and Diseases  
Director and Physician-in-Chief  
University of Cincinnati Heart  
Lung & Vascular Institute  
University of Cincinnati  
College of Medicine  
Cincinnati, Ohio

Joshua Beckman, MD, MS  
Professor of Medicine  
Director, Vascular Medicine Section  
Vanderbilt Translational and Clinical  
Cardiovascular Research Center (VTRACC)  
Vanderbilt University Medical Center  
Nashville, Tennessee

Deepak L. Bhatt, MD, MPH  
FACC, FAHA, FSCAI, FESC  
Executive Director of Interventional  
Cardiovascular Programs,  
Birmingham and Women’s Hospital  
Heart & Vascular Center  
Professor of Medicine,  
Harvard Medical School  
Boston, Massachusetts

Zachary Bloomgarden, MD  
MACE  
Editor, the Journal of Diabetes  
www.jdiabetes.com,  
Clinical Professor  
Icahn School of Medicine at Mount Sinai  
New York, New York

Biykem Bozkurt, MD, PhD  
FHFA, FACC, FAHA, FESC  
FACP  
President, Heart Failure  
Society of America  
The Mary and Gordon Cain Chair  
“Tack” and Deborah Moncure, Jr., Chair  
Professor of Medicine  
Medical Care Line Executive  
DeBakey VA Medical Center  
Director, Winters Center for  
Heart Failure Research  
Associate Director  
Cardiovascular Research Institute  
Vice-Chair of Medicine  
Baylor College of Medicine  
Houston, Texas

Eugene Braunwald, MD  
Distinguished Hersey Professor of  
Medicine Harvard Medical School  
Founding Chairman, TIMI Study Group  
Birmingham and Women’s Hospital  
Boston, Massachusetts

Matthew J. Budoff, MD  
FACC, FAHA  
Professor of Medicine  
David Geffen School of Medicine at UCLA  
Endowed Chair of Preventive Cardiology  
Program Director, Director of Cardiac CT  
Luminaq Institute  
Harbor/UCLA Medical Center  
Division of Cardiology  
Los Angeles, California

Javed Butler, MD, MPH, MBA  
Patrick H. Leboe Chair in  
Cardiovascular Research  
Professor and Chairman,  
Department of Medicine  
University of Mississippi Medical Center  
Jackson, Mississippi

Robert J. Chilton, DO, FACP,  
FACC, FAHA, MACOI, FASCAI  
Professor of Medicine  
Department of Medicine  
Division of Cardiology  
The University of Texas  
Health Science Center  
San Antonio, Texas

David J. Cohen, MD, MSc  
Professor of Medicine  
University of Missouri-Kansas City  
Kansas City, Missouri

Mark E. Cooper, MB BS, PhD,  
FRACP  
Head, Department of Diabetes  
Cardinal Clinical School  
Monash University  
Senior Endocrinologist  
 Alfred Health Clinic  
Melbourne, Australia

David A. D’Alessio, MD  
Professor of Medicine  
Chief, Division of Endocrinology  
Metabolism and Nutrition  
Associate Director, Duke Molecular  
Pharmacology Institute  
Durham, North Carolina

Michael H. Davidson, MD  
FACC, FACP, FNLA  
Professor, Director of the Lipid Clinic  
The University of Chicago Pritzker  
School of Medicine  
Chicago, Illinois

Ralph A. DeFronzo, MD  
Professor of Medicine  
Chief, Diabetes Division  
University of Texas Health Science Center  
at San Antonio (UTHSCSA)  
Deputy Director, Texas Diabetes Institute  
San Antonio, Texas
FACULTY 2020

Stefano Del Prato, MD
Professor of Endocrinology and Metabolism
Chief of the Section of Diabetes
University of Pisa, School of Medicine
Pisa, Italy

Daniel Einhorn, MD
FACP, FACE
President, Diabetes and Endocrine Associates Medical Director
Scripps Whittier Diabetes Institute
Past President, American Association of Clinical Endocrinology
Past President, American College of Endocrinology (ACE)
Associate Editor, Journal of Diabetes
La Jolla, California

Michael E. Farkouh, MD
MSc, FRCPC, FACC, FAHA
Peter Munk Chair in Multinational Clinical Trials
Director, Heart & Stroke Richard Lewar Centre of Excellence,
University of Toronto
Vice-Chair Research & Professor of Medicine, Department of Medicine
University of Toronto
Toronto, Ontario, Canada

Sergio Fazio, MD, PhD
The William and Sonia Conner Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon

Vivian A. Fonseca, MD, FRCP
Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, Louisiana

Alan J. Garber, MD, PhD
MACE
Professor, Departments of Medicine, Biochemistry and Molecular Biology, and Molecular & Cellular Biology
Baylor College of Medicine
Houston, Texas

Peter J. Grant, MD
FRCP, FMedSci
Professor of Medicine and Diabetologist
Honorary Consultant Physician,
Leeds Teaching Hospitals NHS Trust
Division of Cardiovascular & Diabetes Research
University of Leeds
Leeds, United Kingdom

George Grunberger, MD
FACP, FACE
Chairman, Grunberger Diabetas Institute
Clinical Professor, Internal Medicine and Molecular Medicine & Genetics
Wayne State University
School of Medicine
Professor, Internal Medicine
Oakland University William Beaumont
Visiting Professor, Internal Medicine
First Faculty of Medicine
Charles University,
Prague, Czech Republic
Bloomfield Hills, Michigan

Daniel Gudbjartsson, PhD
V.P. of Statistics
eeCODE Genetics
Reykjavik, Iceland

Silvio E. Inzucchi, MD
Professor of Medicine
Yale School of Medicine
Clinical Chief, Endocrinology and Medical Director
Yale Diabetes Center
Yale-New Haven Hospital
New Haven, Connecticut

Paul S. Jellinger, MD, MACE
Professor of Clinical Medicine
Voluntary Faculty
University of Miami
Miller School of Medicine
The Center for Diabetes & Endocrine Care
Past President, AACE & ACE
Hollywood, Florida

Mark Kearney, MBChB
MRCP, MD
British Heart Foundation Professor of Cardiovascular and Diabetes Research
Leeds Institute of Cardiovascular & Metabolic Medicine
Dean of the School of Medicine
University of Leeds
Leeds, United Kingdom

Norman E. Lepor, MD, FACC
Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Attending Cardiologist at the Smidt Cedars-Sinai Heart Institute
Director of Clinical Research
Westside Medical Associates of LA
Co-Director of Cardiovascular Imaging
Westside Medical Imaging in Beverly Hills
Los Angeles, California

Derek LeRoith, MD, PhD
FACP
Professor of Medicine
Director of Research Division of Endocrinology
Diabetes & Bone Disease
Department of Medicine
Icahn School of Medicine at Mt. Sinai
New York, New York

Alice H. Lichtenstein, D.Sc.
Gesherst Professor of Nutrition Science and Policy
Director and Senior Scientist Cardiovascular Nutrition Laboratory
Tufts University
JL USDA Human Nutrition Research Center on Aging
Executive Editor, Tufts Health and Nutrition Letter
Boston, Massachusetts

Myra A. Lipes, MD
Assistant Professor, Medicine
Harvard Medical School
Assistant Professor, Medicine,
Brigham And Women’s Hospital
Investigator, Research Division
Joslin Diabetes Center
Boston, Massachusetts
FACULTY 2020

Irving Kent Loh MD
FACC, FAHA, FCCP, FACP
Chief Medical Officer and Co-Founder, INFERMEDICA
Ventura Heart Institute
Chair, Technology & Innovation, California Chapter, American College of Cardiology
Member, MAPCo, International Telecommunication Union, World Health Organization/UN
Adjunct Lecturer, Department of Medicine, Stanford University
School of Medicine
Thousand Oaks, California

Julie A. Lovshin, MD, PhD
FRCPC
Clinician Scientist
Assistant Professor of Medicine
Division of Endocrinology & Metabolism
University of Toronto
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada

Gina P. Lundberg, MD
FACC, FAHA
Clinical Director
Emory Women’s Heart Center
Associate Professor of Medicine
Emory University School of Medicine
Division of Cardiology
Atlanta, Georgia

Christos S. Mantzoros, MD
DSc, PhD h.c. mult.
Professor of Medicine
Harvard Medical School and Boston University School of Medicine
Chief of Endocrinology, Diabetes and Metabolism
Boston VA Healthcare System
Director of Human Nutrition, Beth Israel Deaconess Medical Center
Editor-in-Chief, Metabolism Clinical & Experimental
Boston, Massachusetts

Nikolaus Marx, MD
FESC, FAHA
Professor of Medicine / Cardiology
Head of the Department of Internal Medicine
University Hospital RWTH Aachen
Aachen, Germany

John McMurray, BSc (Hons)
MB ChB (Hons), MD, FRCP
FESC, FACC, FAHA, FRSE
FMedSci, OBE
Professor of Medical Cardiology and Deputy Director (Clinical)
Institute of Cardiovascular and Medical Sciences
Honorary Consultant Cardiologist
Queen Elizabeth University Hospital
Glasgow, Scotland

Christian W. Mende, MD
FACP, FACC, FASN, FASH, FAHA
Clinical Professor of Medicine
University of California San Diego
La Jolla, California

Robert J. Mentz, MD
FACC, FAHA, FHFAA
Associate Professor of Medicine
Chief, Heart Failure Section
Associate Program Director, Duke Cardiovascular Disease Fellowship
Duke University Medical Center
Durham, North Carolina

David M. Nathan, MD
Director, Diabetes Center and Clinical Research Center
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Steven E. Nissen, MD, MACC
Chief Academic Officer
Heart & Vascular Institute
Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner
School of Medicine
at Case Western Reserve University
Cleveland, Ohio

Neha J. Pagidipati, MD, MPH
Assistant Professor of Medicine,
Division of Cardiology
Director, Duke Cardiometabolic Prevention Program
Associate Program Director
Cardiology Fellowship
Associate Program Director
DCTI Research Fellowship
Duke Clinical Research Institute
Duke University Medical School
Durham, North Carolina

Richard E. Pralley, MD
Samuel E. Crockett
Chair in Diabetes Research
Medical Director, AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Orlando, Florida

Kausik Ray, BSc(Hons)
MBChB, MD, MPhil (Cantab)
FRCP (Lon), FRCP (Ed), FACC
FESC, FAHA
Professor of Public Health
Consultant Cardiologist
Deputy Director of The Imperial Clinical Trials Unit Head of Commercial Trials
Department of Public Health & Primary Care
School of Public Health, Imperial College
NIHR ARC National Lead of Cardiovascular Disease
EAS President Elect
London, United Kingdom

Peter Reaven, MD
Professor of Clinical Medicine
University of Arizona
Director, Diabetes Program
Carl T. Hayden VAMC (111E)
Research Professor
College of Health Solutions
Arizona State University
Phoenix, Arizona
Faculty 2020

Jennifer G. Robinson, MD, MPH
Professor, Departments of Epidemiology & Medicine
Director, Prevention Intervention Center
Carver College of Medicine
University of Iowa
Iowa City, Iowa

Benjamin M. Scirica, MD, MPH
Associate Professor of Medicine, Harvard Medical School
Associate Physician, Brigham and Women’s Hospital
Senior Investigator, TIMI Study Group
Boston, Massachusetts

Michael P. Snyder, PhD
Professor and Chair of Genetics
Director, Center for Genomics and Personalized Medicine
Stanford University School of Medicine
Stanford, California

Laurence Sperling, MD
FACC, FAHA, FACP, FASPC
Katz Professor in Preventive Cardiology
Director of the Emory Heart Disease Prevention Center
Professor of Global Health
Hubert Department of Global Health
Rollins School of Public Health at Emory University
Atlanta, Georgia

Philippe Gabriel Steg, MD
FESC, FACC
Chief, Department of Cardiology
Hôpital Bichat, Assistance Publique–Hôpitaux de Paris
Vice President
Board of the Assistance Publique–Hôpitaux de Paris
Professor of Cardiology,
Université Paris - Diderot
Director, “Clinical Research in Atherosclerosis” Research Team
Coordinator of the NIVASc (InnoVations in Atherosclerosis SCience)
RIU research consortium
Chair of the FACT
Chairman of the French National University Council
Paris, France

Jeffrey Testani, MD, MTR
Associate Professor
Director of Heart Failure Research,
Section of Cardiovascular Medicine
Yale University School of Medicine
New Haven, Connecticut

Muthiah Vaduganathan, MD, MPH
Cardiologist, Brigham and Women’s Hospital
Instructor of Medicine
Harvard Medical School
Boston, Massachusetts

Subodh Verma, MD, PhD
FRCS, FAHA
Cardiac Surgeon
Professor of Surgery and Pharmacology & Toxicology
University of Toronto
Canadi Research Chair in Cardiovascular Surgery
Division of Cardiac Surgery
St. Michael’s Hospital
Toronto, Ontario, Canada

Allen Wang, MD
Duke Center for Atrial Fibrillation
Department of Medicine
Duke University Medical Center
Durham, North Carolina

Matthew R. Weir, MD
Professor and Chief
Nephrology Division
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland